Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2021-04-01
|
| Seri Bilgileri: | Biomedicines |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/2227-9059/9/5/451 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|